T J Liang
Overview
Explore the profile of T J Liang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
2242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liang T, Wang K, Tsai C, Chen I
Ann R Coll Surg Engl
. 2020 Mar;
102(5):e102-e104.
PMID: 32159370
Epigastric hernia involving the falciform ligament is exceptionally rare. Most reported cases are incisional hernia secondary to prior abdominal surgery. We report a case of primary falciform ligament herniation into...
2.
Complications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience
Takyar V, Etzion O, Heller T, Kleiner D, Rotman Y, Ghany M, et al.
Aliment Pharmacol Ther
. 2017 Jan;
45(5):744-753.
PMID: 28074540
Background: Liver biopsy is the gold standard in evaluating liver diseases but is susceptible to complications. Safety data on aspiration needle biopsies remain limited. Aim: To evaluate the safety of...
3.
Takyar V, Surana P, Kleiner D, Wilkins K, Hoofnagle J, Liang T, et al.
Aliment Pharmacol Ther
. 2016 Nov;
45(1):127-138.
PMID: 27813124
Background: Serum fibrosis markers are useful in staging chronic hepatitis B (HBV) and C (HCV) virus but have not been evaluated in chronic hepatitis D virus (HDV). Aim: To evaluate...
4.
Shapovalyants S, Michalev A, Timofeev M, Polushkin V, Volkov V, Oettinger A, et al.
Hernia
. 2015 Nov;
19 Suppl 1:S167-75.
PMID: 26518795
No abstract available.
5.
Noureddin M, Rotman Y, Zhang F, Park H, Rehermann B, Thomas E, et al.
Genes Immun
. 2015 May;
16(5):321-9.
PMID: 26020282
IFNL4 is linked to hepatitis C virus treatment response and type III interferons (IFNs). We studied the functional associations among hepatic expressions of IFNs and IFN-stimulated genes (ISGs), and treatment...
6.
Heller T, Rotman Y, Koh C, Clark S, Haynes-Williams V, Chang R, et al.
Aliment Pharmacol Ther
. 2014 May;
40(1):93-104.
PMID: 24815494
Background: Chronic delta hepatitis virus (HDV) infection rapidly progresses to cirrhosis. Treatment with peginterferon for up to 2 years is often without durable response. Aim: To examine the efficacy and...
7.
Koh C, Heller T, Haynes-Williams V, Hara K, Zhao X, Feld J, et al.
Aliment Pharmacol Ther
. 2013 Mar;
37(9):887-94.
PMID: 23461575
Background: Although the short-term benefits of a sustained virological response (SVR) to interferon-based therapies of chronic hepatitis C (CHC) are well known, the long-term consequences of SVR are less clear....
8.
Ghany M, Feld J, Zhao X, Heller T, Doo E, Rotman Y, et al.
Aliment Pharmacol Ther
. 2012 Mar;
35(9):1027-35.
PMID: 22449251
Background: Combination antiviral therapy holds the promise of increasing response rates while decreasing antiviral resistance, but has yet to be shown to be beneficial or necessary in chronic hepatitis B....
9.
Loomba R, Rivera M, McBurney R, Park Y, Haynes-Williams V, Rehermann B, et al.
Aliment Pharmacol Ther
. 2011 Jan;
33(5):559-65.
PMID: 21198704
Background: Acute hepatitis C has variable modes of presentation and frequently results in chronic infection. Its optimal management has yet to be defined. Aim: To establish natural history and complications...
10.
Rotman Y, Borg B, Soza A, Feld J, Modi A, Loomba R, et al.
Aliment Pharmacol Ther
. 2010 Feb;
31(9):1018-27.
PMID: 20163377
Background: Chronic infection with hepatitis C, genotype 2/3, responds better than other genotypes to peginterferon and ribavirin treatment. We hypothesized that a lower dose of peginterferon would be as effective,...